Mobile

Efficacy and safety of anti-cytomegalovirus prophylaxis versus pre-emptive approaches with valganciclovir in heart transplant recipients treated with everolimus or mycophenolate. A randomized open-lab...

Mise à jour : Il y a 4 ans
Référence : EUCTR2008-006980-35

Efficacy and safety of anti-cytomegalovirus prophylaxis versus pre-emptive approaches with valganciclovir in heart transplant recipients treated with everolimus or mycophenolate. A randomized open-label study for prevention of cardiac allograft vasculopathy

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

To compare development of CAV detected by intravascular ultrasound (IVUS) in heart recipients randomized either to a pre-emptive anti-CMV strategy or universal anti-CMV prophylaxis based on valganciclovir administration. CAV will be defined by the change in maximal intimal thickness between baseline and year-1 IVUS, which is the major surrogate measure for long-term survival after heart transplantation

Critère d'inclusion

  • Heart Transplantation

Liens